IL287665A - Combined treatments including apremilaste and tyk2 inhibitors - Google Patents

Combined treatments including apremilaste and tyk2 inhibitors

Info

Publication number
IL287665A
IL287665A IL287665A IL28766521A IL287665A IL 287665 A IL287665 A IL 287665A IL 287665 A IL287665 A IL 287665A IL 28766521 A IL28766521 A IL 28766521A IL 287665 A IL287665 A IL 287665A
Authority
IL
Israel
Prior art keywords
day
substituted
per day
dioxo
methylsulfonyl
Prior art date
Application number
IL287665A
Other languages
English (en)
Hebrew (he)
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of IL287665A publication Critical patent/IL287665A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL287665A 2019-04-30 2019-04-30 Combined treatments including apremilaste and tyk2 inhibitors IL287665A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (fr) 2019-04-30 2019-04-30 Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2

Publications (1)

Publication Number Publication Date
IL287665A true IL287665A (en) 2022-07-01

Family

ID=66476870

Family Applications (2)

Application Number Title Priority Date Filing Date
IL287665A IL287665A (en) 2019-04-30 2019-04-30 Combined treatments including apremilaste and tyk2 inhibitors
IL287670A IL287670A (en) 2019-04-30 2021-10-28 Combined treatments including apremilaste and tyk2 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL287670A IL287670A (en) 2019-04-30 2021-10-28 Combined treatments including apremilaste and tyk2 inhibitors

Country Status (14)

Country Link
EP (2) EP3962475A1 (fr)
JP (2) JP2022537877A (fr)
KR (2) KR20220002488A (fr)
CN (3) CN114269336A (fr)
AU (2) AU2019443366A1 (fr)
BR (2) BR112021021809A2 (fr)
CA (2) CA3138473A1 (fr)
CL (1) CL2021002847A1 (fr)
CO (2) CO2021015614A2 (fr)
IL (2) IL287665A (fr)
MA (1) MA55799A (fr)
MX (2) MX2021013317A (fr)
SG (2) SG11202112043PA (fr)
WO (2) WO2020222773A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112043PA (en) * 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors
CA3208361A1 (fr) 2021-02-19 2022-08-25 Anjali Pandey Inhibiteurs de tyk2 et leurs utilisations
EP4294806A1 (fr) 2021-02-19 2023-12-27 Sudo Biosciences Limited Inhibiteurs de tyk2 et leurs utilisations
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
JP7740849B2 (ja) * 2021-05-04 2025-09-17 シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド 含窒素複素環ピリジン化合物
EP4404930A1 (fr) * 2021-09-23 2024-07-31 Bristol-Myers Squibb Company Procédés de traitement de troubles de la perte des cheveux avec des inhibiteurs de tyk2
EP4423086A1 (fr) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Agents de dégradation de tyk2 et leurs utilisations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
JP2014500254A (ja) 2010-11-09 2014-01-09 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
JP6022548B2 (ja) * 2011-04-28 2016-11-09 セルジーン コーポレイション Ｐｄｅ４阻害剤を自己免疫疾患及び炎症性疾患の治療及び管理に使用する方法及び組成物
RS60415B1 (sr) * 2011-12-27 2020-07-31 Amgen (Europe) GmbH Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona
CN104159891B (zh) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
WO2013146963A1 (fr) 2012-03-28 2013-10-03 武田薬品工業株式会社 Composé hétérocyclique
BR112014029310A2 (pt) 2012-05-24 2018-06-26 Cellzome Ltd análogos da pirimidina heterocíclica como inibidores da tyk2
ES2648226T3 (es) 2012-11-08 2017-12-29 Bristol-Myers Squibb Company Compuestos de pirimidina sustituidos con alquilamida útiles en la modulación de IL-12, IL-23 y/o IFN
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
WO2014151180A1 (fr) * 2013-03-14 2014-09-25 Celgene Corporation Traitement de la polyarthrite psoriasique à l'aide d'apremilast
JPWO2015016206A1 (ja) 2013-07-30 2017-03-02 武田薬品工業株式会社 複素環化合物
MX369974B (es) 2013-09-03 2019-11-27 Sareum Ltd Compuestos farmaceuticos.
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
WO2015091584A1 (fr) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Composés de thiazolopyridine, compositions et leur utilisation comme inhibiteurs de la kinase tyk2
US9834548B2 (en) * 2014-02-14 2017-12-05 Portola Pharmaceuticals, Inc. Pyridazine compounds as JAK inhibitors
WO2015131080A1 (fr) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
MX2016014384A (es) * 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
US10092541B2 (en) * 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
NO2721710T3 (fr) 2014-08-21 2018-03-31
WO2016047678A1 (fr) 2014-09-25 2016-03-31 武田薬品工業株式会社 Composé hétérocyclique
TWI788655B (zh) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
TWI707852B (zh) 2015-09-02 2020-10-21 美商林伯士拉克許米公司 Tyk2 抑制劑及其用途
CN109071546B (zh) 2016-02-24 2021-03-02 辉瑞大药厂 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
ES2902995T3 (es) 2016-10-07 2022-03-30 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
US10323036B2 (en) 2016-10-14 2019-06-18 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
EP3528816A4 (fr) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
KR102477063B1 (ko) 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
EP3541817B1 (fr) 2016-11-17 2020-12-23 Bristol-Myers Squibb Company Modulateurs d'imidazopyridazine d'il-12, il-23 et/ou ifn-alpha
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
TW202515876A (zh) * 2017-03-08 2025-04-16 日商武田藥品工業股份有限公司 Tyk2抑制劑及其用途
SG11202112043PA (en) * 2019-04-30 2021-11-29 Celgene Corp Combination therapies comprising apremilast and tyk2 inhibitors

Also Published As

Publication number Publication date
BR112021021826A8 (pt) 2022-06-21
KR20220002489A (ko) 2022-01-06
SG11202112043PA (en) 2021-11-29
CN114269336A (zh) 2022-04-01
CA3138686A1 (fr) 2020-11-05
CN119454692A (zh) 2025-02-18
JP2022537877A (ja) 2022-08-31
WO2020223431A1 (fr) 2020-11-05
MX2021013318A (es) 2022-01-31
SG11202112018YA (en) 2021-11-29
AU2019443366A1 (en) 2021-12-02
CO2021015614A2 (es) 2021-12-10
AU2020266143A1 (en) 2021-12-02
EP3962476A1 (fr) 2022-03-09
MA55799A (fr) 2022-03-09
CN114206333A (zh) 2022-03-18
CL2021002847A1 (es) 2022-07-22
EP3962475A1 (fr) 2022-03-09
JP7453251B2 (ja) 2024-03-19
MX2021013317A (es) 2022-01-18
BR112021021826A2 (pt) 2022-01-04
IL287670A (en) 2021-12-01
WO2020222773A1 (fr) 2020-11-05
CA3138473A1 (fr) 2020-11-05
JP2022537878A (ja) 2022-08-31
KR20220002488A (ko) 2022-01-06
BR112021021809A2 (pt) 2022-01-04
CO2021015622A2 (es) 2022-02-28

Similar Documents

Publication Publication Date Title
IL287665A (en) Combined treatments including apremilaste and tyk2 inhibitors
US20220339151A1 (en) Combination therapies comprising apremilast and tyk2 inhibitors
CN105311030A (zh) 用于抗肿瘤的螺取代化合物
JP3832229B2 (ja) フェニルエテンスルホンアミド誘導体含有医薬
JP2025510813A (ja) Ｔｙｋ２阻害剤及びその使用
WO2017118584A1 (fr) Orvépitant pour le traitement d'une toux chronique
WO2025157117A1 (fr) Utilisation de formes salines de composé et de formes cristallines de celui-ci dans le traitement d'une insuffisance cardiaque avec fraction d'éjection préservée
JP2024069223A (ja) 乾癬性関節炎の治療方法
US20250084035A1 (en) Polymorphic form of meisoindigo and modified formulation of meisoindigo
JP2005526022A5 (ja) 関節リウマチの処置
EA046759B1 (ru) Комбинированные терапии, содержащие апремиласт и ингибиторы tyk2
JPH08239322A (ja) ピロリジノン誘導体を含有する医薬組成物
WO2025002076A1 (fr) Utilisations d'un inhibiteur de mk2 dans la préparation de médicaments pour la prévention et/ou le traitement de maladies
CN121443296A (zh) 化合物1在治疗或预防肺纤维化或伴有纤维化的肺部疾病等疾病中的应用
TW200524612A (en) Combinations of a pyrimidine containing NNRTI with RT inhibitors